145 related articles for article (PubMed ID: 36931548)
1. Patient's experience and satisfaction with self-administered subcutaneous depot medroxyprogesterone acetate use during the first year of COVID-19.
Smith TJ; Urdanigo TK; Shroff N; Rubin SE
Contraception; 2023 Jul; 123():110008. PubMed ID: 36931548
[TBL] [Abstract][Full Text] [Related]
2. An implementation project to expand access to self-administered depot medroxyprogesterone acetate (DMPA).
Katz M; Newmark RL; Aronstam A; O'Grady N; Strome S; Rafie S; Karlin J
Contraception; 2020 Dec; 102(6):392-395. PubMed ID: 32931811
[TBL] [Abstract][Full Text] [Related]
3. A Pilot Study of Adolescent and Young Adult Experience with Subcutaneous Depot Medroxyprogesterone Acetate.
Wernick HJ; Wentzel E; Jackson K; Schmuhl K; Valenti O; Bonny AE; Berlan ED
J Pediatr Adolesc Gynecol; 2023 Dec; 36(6):549-552. PubMed ID: 37354986
[TBL] [Abstract][Full Text] [Related]
4. Provision of DMPA-SC for self-administration in different practice settings during the COVID-19 pandemic: Data from providers across the United States.
Comfort AB; Alvarez A; Goodman S; Upadhyay U; Mengesha B; Karlin J; Shokat M; Blum M; Harper CC
Contraception; 2024 Mar; 131():110360. PubMed ID: 38158075
[TBL] [Abstract][Full Text] [Related]
5. Society of Family Planning committee consensus on self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC).
Kohn JE; Berlan ED; Tang JH; Beasley A
Contraception; 2022 Aug; 112():11-13. PubMed ID: 35378085
[TBL] [Abstract][Full Text] [Related]
6. Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States.
Upadhyay UD; Zlidar VM; Foster DG
Contraception; 2016 Oct; 94(4):303-13. PubMed ID: 27326938
[TBL] [Abstract][Full Text] [Related]
7. Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate.
Beasley A; White KO; Cremers S; Westhoff C
Contraception; 2014 May; 89(5):352-6. PubMed ID: 24656555
[TBL] [Abstract][Full Text] [Related]
8. Women's satisfaction, use, storage and disposal of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) during a randomized trial.
Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Dal Santo L; Ngwira B
Contraception; 2018 Nov; 98(5):418-422. PubMed ID: 29758176
[TBL] [Abstract][Full Text] [Related]
9. Implementation strategies to scale up self-administered depot medroxyprogesterone acetate subcutaneous injectable contraception: a scoping review.
Aderoba AK; Steyn PS; Kiarie JN
Syst Rev; 2023 Jul; 12(1):114. PubMed ID: 37403147
[TBL] [Abstract][Full Text] [Related]
10. Predictors of DMPA-SC continuation among urban Nigerian women: the influence of counseling quality and side effects.
Liu J; Shen J; Diamond-Smith N
Contraception; 2018 Nov; 98(5):430-437. PubMed ID: 29733817
[TBL] [Abstract][Full Text] [Related]
11. Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial.
Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Dal Santo L; Ngwira B
Lancet Glob Health; 2018 May; 6(5):e568-e578. PubMed ID: 29526707
[TBL] [Abstract][Full Text] [Related]
12. Pharmacist-administered subcutaneous depot medroxyprogesterone acetate: a pilot randomized controlled trial.
Picardo C; Ferreri S
Contraception; 2010 Aug; 82(2):160-7. PubMed ID: 20654757
[TBL] [Abstract][Full Text] [Related]
13. Continuation of self-injected versus provider-administered contraception in Senegal: a nonrandomized, prospective cohort study.
Cover J; Ba M; Drake JK; NDiaye MD
Contraception; 2019 Feb; 99(2):137-141. PubMed ID: 30439358
[TBL] [Abstract][Full Text] [Related]
14. Continuation of subcutaneous or intramuscular injectable contraception when administered by facility-based and community health workers: findings from a prospective cohort study in Burkina Faso and Uganda.
MacLachlan E; Atuyambe LM; Millogo T; Guiella G; Yaro S; Kasasa S; Bukenya J; Nyabigambo A; Mubiru F; Tumusiime J; Onadja Y; Zan LM; Goeum/Sanon C; Kouanda S; Namagembe A
Contraception; 2018 Nov; 98(5):423-429. PubMed ID: 30125558
[TBL] [Abstract][Full Text] [Related]
15. Self-administration of subcutaneous depot medroxyprogesterone acetate by adolescent women.
Williams RL; Hensel DJ; Fortenberry JD
Contraception; 2013 Sep; 88(3):401-7. PubMed ID: 23294549
[TBL] [Abstract][Full Text] [Related]
16. Patient experiences switching from in-clinic to self-administration of injectable contraception in two Western US states.
Newmark RL; Hodge CC; Shih G; Karlin J
Perspect Sex Reprod Health; 2024 Jul; ():. PubMed ID: 38965382
[TBL] [Abstract][Full Text] [Related]
17. Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate.
Curtis KM; Nguyen A; Reeves JA; Clark EA; Folger SG; Whiteman MK
MMWR Morb Mortal Wkly Rep; 2021 May; 70(20):739-743. PubMed ID: 34014910
[TBL] [Abstract][Full Text] [Related]
18. Introduction of Community-Based Provision of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in Benin: Programmatic Results.
Okegbe T; Affo J; Djihoun F; Zannou A; Hounyo O; Ahounou G; Bangbola KA; Harris N
Glob Health Sci Pract; 2019 Jun; 7(2):228-239. PubMed ID: 31171559
[TBL] [Abstract][Full Text] [Related]
19. Increased 1-year continuation of DMPA among women randomized to self-administration: results from a randomized controlled trial at Planned Parenthood.
Kohn JE; Simons HR; Della Badia L; Draper E; Morfesis J; Talmont E; Beasley A; McDonald M; Westhoff CL
Contraception; 2018 Mar; 97(3):198-204. PubMed ID: 29246818
[TBL] [Abstract][Full Text] [Related]
20. Factors Affecting Continued Use of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC): A Secondary Analysis of a 1-Year Randomized Trial in Malawi.
Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Santo LD; Ngwira B
Glob Health Sci Pract; 2019 Mar; 7(1):54-65. PubMed ID: 30894394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
